Ha Tay Pharmaceutical JSC (HNX:DHT)
Vietnam flag Vietnam · Delayed Price · Currency is VND
49,900
+1,000 (2.04%)
At close: Nov 3, 2026

Ha Tay Pharmaceutical JSC Balance Sheet

Millions VND. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Jan '25 Jan '24 Jan '23 Jan '22
Cash & Equivalents
117,37684,33790,270301,79093,13259,669
Short-Term Investments
100,286150,00090,00080,00059,799362,814
Cash & Short-Term Investments
217,662234,337180,270381,790152,931422,483
Cash Growth
5.05%29.99%-52.78%149.65%-63.80%446.74%
Accounts Receivable
126,076107,755124,09689,463109,915121,112
Other Receivables
411.873,2802,6918,4121,68119,673
Receivables
126,488111,035126,78797,875111,596140,786
Inventory
313,839513,397527,935378,908460,629339,706
Other Current Assets
37,35637,97189,869150,099285,781104,311
Total Current Assets
695,345896,739924,8611,008,6731,010,9371,007,287
Property, Plant & Equipment
900,7671,000,716976,101791,736442,074212,752
Long-Term Investments
20,65219,86019,33633,96911,1449,486
Other Intangible Assets
1,3771,3771,3771,3771,5931,810
Long-Term Deferred Tax Assets
713.671,186----
Other Long-Term Assets
93,99712,0394,6312,5103,7546,256
Total Assets
1,712,8511,931,9171,926,3051,838,2641,469,5021,237,591

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Jan '25 Jan '24 Jan '23 Jan '22
Accounts Payable
237,282261,261235,207146,324196,573113,994
Accrued Expenses
25,10733,50020,67512,20417,11915,513
Short-Term Debt
160,565236,151359,429333,483234,630289,429
Current Portion of Long-Term Debt
-13,84513,845---
Current Income Taxes Payable
-4,5505,0704,9588,6605,450
Current Unearned Revenue
4,6386,418909.31,008785.26551.02
Other Current Liabilities
61,923178,298132,61898,012105,37454,142
Total Current Liabilities
489,515734,023767,752595,988563,143479,079
Long-Term Debt
83,06883,06896,913170,218102,213-
Other Long-Term Liabilities
3,4383,6264,8804,9085,3065,167
Total Liabilities
576,022820,717869,545771,114670,662484,245

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Jan '25 Jan '24 Jan '23 Jan '22
Common Stock
905,756905,756823,418823,418264,088264,088
Additional Paid-In Capital
37,28237,28297,32097,320315,934315,934
Retained Earnings
172,678121,10590,28099,00681,83179,048
Treasury Stock
-8,084-8,084-8,084-8,084-8,084-8,084
Comprehensive Income & Other
2,23626,61226,61226,612119,57278,779
Total Common Equity
1,109,8681,082,6711,029,5461,038,273773,341729,766
Minority Interest
26,96128,52927,21428,87725,49923,580
Shareholders' Equity
1,136,8291,111,2011,056,7601,067,150798,841753,345
Total Liabilities & Equity
1,712,8511,931,9171,926,3051,838,2641,469,5021,237,591

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Jan '25 Jan '24 Jan '23 Jan '22
Total Debt
243,633333,064470,187503,700336,844289,429
Net Cash (Debt)
-25,971-98,727-289,917-121,910-183,912133,054
Net Cash Growth
------
Net Cash Per Share
--1079.07-2909.89-1992.39-2055.621498.67
Filing Date Shares Outstanding
-99.6399.6399.6389.4789.47
Total Common Shares Outstanding
-99.6399.6399.6389.4789.47
Working Capital
205,830162,717157,109412,684447,795528,208
Book Value Per Share
-10866.7610333.5210421.108643.788156.72
Tangible Book Value
1,108,4921,081,2951,028,1701,036,896771,748727,956
Tangible Book Value Per Share
-10852.9510319.7010407.298625.978136.49
Buildings
-168,480165,434150,724149,255148,602
Machinery
-277,573272,572234,134209,230200,702
Construction In Progress
11,054827,184790,110638,852301,45164,931